<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178811</url>
  </required_header>
  <id_info>
    <org_study_id>Benign Prostatic Hyperplasia</org_study_id>
    <nct_id>NCT04178811</nct_id>
  </id_info>
  <brief_title>Comparison Between HoLEP and PUL in Management of BPH</brief_title>
  <official_title>Comparative Study Between Holmium Laser Enucleation of Prostate and Prostatic Uretheral Lift in Management of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison between two minimally invasive surgical modalities in management of Benign
      Prostatic Hyperplasia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms
      (LUTS) in aging men. LUTS is categorized as any combination of symptoms related to storage,
      voiding, or postmicturition. The management of bothersome BPH includes watchful waiting,
      pharmacotherapy, and surgery. The most common surgical approach is transurethral resection of
      the prostate (TURP). TURP can improve voiding symptoms dramatically. However, TURP is
      correlated with a 20% rate of perioperative and long-term complications. In addition, elderly
      patients usually have some comorbidities that require complex medical regimens that may
      further complicate perioperative management. Therefore, new treatments that are more
      minimally invasive and more effective are needed to manage patients with LUTS.The advent of
      Holmium laser enucleation of the prostate (HoLEP) has triggered a paradigm shift in the
      surgical management of BPH; with improved functional outcomes, lower complication rates and
      length of stay, and fewer repeat procedures required at 5- 10 years versus TURP, and open
      prostatectomy. HoLEP is now regarded as the gold standard for BPH.Prostatic urethral lift
      (PUL) is a minimally invasive surgery that uses small implants under cystoscopic guidance
      which serve to retract the obstructing lateral lobes and make an open, continuous voiding
      channel through the prostate fossa, from the verumontanum up to the bladder neck. PUL has
      been demonstrated to provide significant symptom improve with low morbidity, including
      preservation of sexual function.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IPSS (International Prostate Symptom Score)</measure>
    <time_frame>One year</time_frame>
    <description>International Prostate Symptom Score (IPSS). Minimum Score is Zero. Maximum Score is 35. 0-7 means mildly symptomatic and so good outcome. 8-19 means moderately symptomatic and so worse outcome. 20-35 means severely symptomatic and so worst outcome. Briefly,The lower the score, the better the outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Holmium Laser Enucleation of Prostate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of Holmium Laser Enucleation of Prostate in Management of Benign Prostatic Hyperplasia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostatic Uretheral Lift</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of Holmium Prostatic Uretheral Lift in Management of Benign Prostatic Hyperplasia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holmium Laser Enucleation of Prostate and Prostatic Uretheral Lift</intervention_name>
    <description>Use of Holmium Laser Enucleation of Prostate and Prostatic Uretheral Lift in management of Benign Prostatic Hyperplasia</description>
    <arm_group_label>Holmium Laser Enucleation of Prostate</arm_group_label>
    <arm_group_label>Prostatic Uretheral Lift</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ˃ 50 years.

          -  Prostate volume 20-70 mL (on ultrasound).

          -  IPSS(International Prostate Symptom Score) ˃ 12.

          -  Qmax(Peak Flow Rate) ˂ 15 mL/s.

          -  PVR(post-void residual urine) ˂ 350 mL

        Exclusion Criteria:

          -  Obstructive median lobe.

          -  Active urinary tract infection.

          -  PSA (Prostate Specific Antigen) ˃ 10 ng/mL (unless negative prostatic biopsy).

          -  Prostatitis within past 1 year.

          -  History of urinary retention

          -  Previous BPH surgery.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed A El-Gammal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdel-Moneam A El-Haggagy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman Mahdy, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mostafa M Mostafa, MsC</last_name>
    <phone>00201000740478</phone>
    <email>mostafamostafa@aun.edu.eg</email>
  </overall_contact>
  <reference>
    <citation>Sivarajan G, Borofsky MS, Shah O, Lingeman JE, Lepor H. The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. Rev Urol. 2015;17(3):140-9.</citation>
    <PMID>26543428</PMID>
  </reference>
  <reference>
    <citation>Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J; International Scientific Committee. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009 Apr;181(4):1779-87. doi: 10.1016/j.juro.2008.11.127. Epub 2009 Feb 23.</citation>
    <PMID>19233402</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Lee KS, Kim TH. Evaluation of Clinical Outcomes of Prostatic Urethral Lift for Benign Prostatic Hyperplasia: An Asian Population Study. World J Mens Health. 2020 Jul;38(3):338-344. doi: 10.5534/wjmh.190015. Epub 2019 Jul 30.</citation>
    <PMID>31385478</PMID>
  </reference>
  <reference>
    <citation>Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006 Nov;50(5):969-79; discussion 980. Epub 2006 Jan 30.</citation>
    <PMID>16469429</PMID>
  </reference>
  <reference>
    <citation>Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'dow J, Nordling J, de la Rosette JJ; European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013 Jul;64(1):118-40. doi: 10.1016/j.eururo.2013.03.004. Epub 2013 Mar 13. Review.</citation>
    <PMID>23541338</PMID>
  </reference>
  <reference>
    <citation>Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Patterson JM, Fahrenkrug L, Schoenthaler M, Sonksen J. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017 May;119(5):767-775. doi: 10.1111/bju.13714. Epub 2016 Dec 21.</citation>
    <PMID>27862831</PMID>
  </reference>
  <reference>
    <citation>Miano R, De Nunzio C, Asimakopoulos AD, Germani S, Tubaro A. Treatment options for benign prostatic hyperplasia in older men. Med Sci Monit. 2008 Jul;14(7):RA94-102. Review.</citation>
    <PMID>18591930</PMID>
  </reference>
  <reference>
    <citation>Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG; Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008 Jul;180(1):246-9. doi: 10.1016/j.juro.2008.03.058. Epub 2008 May 21.</citation>
    <PMID>18499179</PMID>
  </reference>
  <reference>
    <citation>Baquero GA, Rich MW. Perioperative care in older adults. J Geriatr Cardiol. 2015 Sep;12(5):465-9. doi: 10.11909/j.issn.1671-5411.2015.05.018.</citation>
    <PMID>26512235</PMID>
  </reference>
  <reference>
    <citation>Bell C, Moore SL, Gill A, Obi-Njoku O, Hughes SF, Saleemi A, Ellis G, Khan F, Shergill IS. Safety and efficacy of Holmium laser enucleation of the prostate (HoLEP) in patients with previous transperineal biopsy (TPB): outcomes from a dual-centre case-control study. BMC Urol. 2019 Oct 22;19(1):97. doi: 10.1186/s12894-019-0523-z.</citation>
    <PMID>31640663</PMID>
  </reference>
  <reference>
    <citation>Michalak J, Tzou D, Funk J. HoLEP: the gold standard for the surgical management of BPH in the 21(st) Century. Am J Clin Exp Urol. 2015 Apr 25;3(1):36-42. eCollection 2015.</citation>
    <PMID>26069886</PMID>
  </reference>
  <reference>
    <citation>Vincent MW, Gilling PJ. HoLEP has come of age. World J Urol. 2015 Apr;33(4):487-93. doi: 10.1007/s00345-014-1443-x. Epub 2014 Nov 22. Review.</citation>
    <PMID>25416347</PMID>
  </reference>
  <reference>
    <citation>Yin L, Teng J, Huang CJ, Zhang X, Xu D. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. J Endourol. 2013 May;27(5):604-11. doi: 10.1089/end.2012.0505. Epub 2013 Feb 1. Review.</citation>
    <PMID>23167266</PMID>
  </reference>
  <reference>
    <citation>Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, Chin PT, Woo HH. Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014 Apr;113(4):615-22. doi: 10.1111/bju.12540.</citation>
    <PMID>24765680</PMID>
  </reference>
  <reference>
    <citation>Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017 Jun;24(3):8802-8813.</citation>
    <PMID>28646935</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mostafa Mohamed Atef Abdelaziz Mostafa</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

